Viacheslav Artyushenko, art photonics GmbH, 12489 Berlin, Germany
A. Bogomolov, art photonics GmbH, 12489 Berlin, Germany
F. Schulte, art photonics GmbH, 12489 Berlin, Germany
I. Usenov, art photonics GmbH, 12489 Berlin, Germany
O. Minet, Charite University Hospital – AG MP/OD, 14195 Berlin, Germany
U. Zabarylo, Charite University Hospital – AG MP/OD, 14195 Berlin, Germany
According to the world cancer report in 2014 cancer is one of the leading causes for morbidity and mortality worldwide. Around 14 million new cases and 8.2 million cancer related deaths were registered in 2012, and the number of new cancer patients diagnosed each year will rise by 20% between 2002 and 2020. Reports in the literature show that up to 30% of surgical procedures result in irradical (incomplete) removal of the tumor. The task to define tumor margins in-vivo is a great challenge, and optical spectroscopy may solve this problem.
Malignant and healthy tissues may be differentiated by fluorescence or molecular spectroscopy methods: Raman scattering, IR-absorption or diffuse reflection. To select the best method or their best combination we use all of them for the same samples of normal and cancer tissues of kidney in-vitro and to find the best one in sensitivity, specificity and accuracy.
Looking for the future clinical applications any spectral system or sensor must be used with flexible and tiny fiber probes – to be disposable or sterilizable. The most promising fiber solutions for cancer screening and tumor margin diagnostics will be compared, starting from the research spectroscopy systems used in a broad 0.3-16µm-range up to the most advanced fiber systems already used in clinics. Possible advantages of a multispectral tissue analysis will be discussed to yield more sensitive, more specific and precise in-vivo detection of tumor margins – taking into account the possibilities to reduce cost and dimensions of fiber sensors.
Dr. Viacheslav Artyushenko
art photonics GmbH, President
Page views: 1804